Patent · US Active

Antibody-drug conjugate produced by binding through linker having hydrophilic structure

US10729782B2 · kind B2 · utility

15Cited by

16References

13Claims

0Family size

Assignee

DAIICHI SANKYO COMPANY, LIMITED · JP

Inventors

Hiroyuki Naito · Tokyo, JP
Takashi Nakada · Tokyo, JP
Masao Yoshida · Tokyo, JP
Shinji Ashida · Tokyo, JP
Takeshi Masuda · Tokyo, JP
Hideki Miyazaki · Tokyo, JP
Yuji Kasuya · Tokyo, JP
Yuki Abe · Tokyo, JP
Yusuke Ogitani · Tokyo, JP

Key dates

Filing date	Nov 22, 2017
Grant date	Aug 4, 2020
Priority date	—
Expiry date	Nov 22, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K16/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula (I) is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- or -L1-L2-LP- wherein the antibody is connected to the terminal of L1, the antitumor compound is connected to the terminal of Lc or LP, and any one or two or more of linkers of L1, L2, and LP has a hydrophilic structure.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.